Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 30:9:137-47.
doi: 10.4137/CMO.S31586. eCollection 2015.

Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Adam M Brufsky  1
Affiliations
Review

Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Adam M Brufsky. Clin Med Insights Oncol. .

Abstract

Global guidelines for the management of locally advanced or metastatic hormone receptor-positive (HR-positive), human epidermal growth factor 2-negative (HER2-negative) breast cancer recommend endocrine therapy as first-line treatment for all patients, regardless of age or postmenopausal status. However, current practice patterns in the United States and Europe suggest that these modes of therapy are not being used as recommended, and many patients with advanced HR-positive, HER2-negative disease are being treated first-line with chemotherapy or switched to chemotherapy after a single endocrine therapy. Given that chemotherapy is associated with increased toxicity and reduced quality of life (QOL) compared with endocrine therapy, prolonging the duration of response obtained with endocrine therapy may help delay chemotherapy and its attendant toxicities. Several strategies to delay or overcome endocrine resistance and thereby postpone chemotherapy have been explored, including the use of second-line endocrine agents with different mechanisms of action, adding targeted agents that inhibit specific resistance pathways, and adding agents that act in complementary or synergistic ways to inhibit tumor cell proliferation. This review analyzes the different therapy options available to HR-positive, HER2-negative patients with advanced breast cancer that can be used to delay chemotherapy and enhance QOL.

Keywords: HR-positive; breast cancer; delaying chemotherapy; targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Emerging targeted agents against breast cancer under clinical development. Reprinted with permission from Ref .
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. International Agency for Research on Cancer [Accessed September 21, 2015];GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012 http://globocan.iarc.fr/Default.aspx.
    1. American Cancer Society Cancer Facts and Figures 2015. 2015. [Accessed September 22, 2015]. Available at: http://www.cancer.org/acs/groups/content/@editorial/documents/document/a....
    1. American Cancer Society Breast Cancer Facts and Figures 2013–2014. 2013. [Accessed September 21, 2015]. Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/ac....
    1. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii, 11–9. - PubMed
    1. National Cancer Institute SEER Stat Fact Sheets. Breast. 2015. [Accessed September 21, 2015]. Available at: http://seer.cancer.gov/statfacts/html/breast.html.